Evidências científicas sobre o manejo do adenocarcinoma retal / Scientific evidence on the management of rectal adenocarcinoma

Authors

  • Karinne Nancy Sena Rocha
  • Letícia Hermont Azevedo
  • Michelle Paz De Araujo
  • Weslley Rodrigues Oliveira
  • Camila Bicalho Murta
  • Laís Soares Marques
  • Ana Beatriz Carvalho Drumond
  • Nadábia Ferreira Alves
  • Daniel Zanini Bernardino De Souza

DOI:

https://doi.org/10.34119/bjhrv5n1-033

Keywords:

Adenocarcinoma, Quimioterapia Adjuvante, Terapia Neoadjuvante.

Abstract

A ressecção cirúrgica é a base da terapia curativa para o adenocarcinoma retal, a cirurgia por si só fornece uma alta taxa de cura apenas para pacientes em estágio inicial da doença, a adição de quimioterapia e radioterapia antes e depois da cirurgia parece melhorar o prognóstico da doença. A radioterapia emergiu como um componente importante da terapia adjuvante para câncer retal por causa dos padrões distintos de falha após a ressecção.  A terapia neoadjuvante em vez de adjuvante, quimiorradioterapia de longa duração ou RT de curta duração sozinha, é uma abordagem preferida para pacientes com transmural ou tumores com nódulo-positivo, principalmente se estiverem baixos no reto e para aqueles com fáscia mesorretal positiva ou ameaçada. As vantagens da abordagem neoadjuvante incluem melhor controle local, uma maior probabilidade de cirurgia para salvar o esfíncter, um menor risco de disfunção intestinal pós-tratamento e um menor risco de estenose anastomótica.

References

Minsky BD, Mies C, Recht A, et al. Resectable adenocarcinoma of the rectosigmoid and rectum. I. Patterns of failure and survival. Cancer 1988; 61:1408.

Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28:iv22.

Rich T, Gunderson LL, Lew R, et al. Patterns of recurrence of rectal cancer after potentially curative surgery. Cancer 1983; 52:1317.

Schüller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45:291.

National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology.

Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2012; 30:1553.

Reimers MS, Kuppen PJ, Lee M, et al. Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients. J Natl Cancer Inst 2014; 106.

Das P. Rectal cancer: do protons have prospects? J Gastrointest Oncol 2014; 5:1.

Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med 1985; 312:1465.

Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991; 324:709.

NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990; 264:1444.

O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994; 331:502.

Tepper JE, O'Connell MJ, Petroni GR, et al. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. J Clin Oncol 1997; 15:2030.

Tepper JE, O'Connell M, Niedzwiecki D, et al. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114. J Clin Oncol 2002; 20:1744.

Gieschke R, Burger HU, Reigner B, et al. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. Br J Clin Pharmacol 2003; 55:252.

Kalofonos HP, Bamias A, Koutras A, et al. A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: a Hellenic Cooperative Oncology Group Study. Eur J Cancer 2008; 44:1693.

Kim TW, Lee JH, Lee JH, et al. Randomized trial of postoperative adjuvant therapy in Stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: 10-year follow-up. Int J Radiat Oncol Biol Phys 2011; 81:1025.

Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351:1731.

Akasu T, Moriya Y, Ohashi Y, et al. Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial. Jpn J Clin Oncol 2006; 36:237.

Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 2004; 22:1785.

Published

2022-01-11

How to Cite

ROCHA, K. N. S.; AZEVEDO, L. H.; DE ARAUJO, M. P.; OLIVEIRA, W. R.; MURTA, C. B.; MARQUES, L. S.; DRUMOND, A. B. C.; ALVES, N. F.; DE SOUZA, D. Z. B. Evidências científicas sobre o manejo do adenocarcinoma retal / Scientific evidence on the management of rectal adenocarcinoma. Brazilian Journal of Health Review, [S. l.], v. 5, n. 1, p. 388–409, 2022. DOI: 10.34119/bjhrv5n1-033. Disponível em: https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/42482. Acesso em: 29 mar. 2024.

Issue

Section

Original Papers